让数据说话:胚胎选择中需考虑嵌合体
该文指出染色体嵌合体在人类胚胎中已记录三十年,早期PGT-A因技术限制未检测嵌合体,可能导致误诊。现代PGT-A可识别中间拷贝数信号,近期数据显示嵌合体及其特定特征与不同临床结局相关。结论是临床胚胎选择应考虑嵌合体以改善决策。
要点
- 早期PGT-A未检测嵌合体,可能造成误诊和不良临床后果。
- 现代PGT-A可识别嵌合体,临床不可避免需管理此类胚胎。
- 嵌合体及其特定特征与不同临床结局相关,应纳入胚胎选择。
核心结论
- 嵌合体应被考虑用于更明智和改善的临床胚胎选择。
研究设计与样本
- 本文为综述/评论类文章,讨论近期关于PGT-A检测嵌合体与临床结局的数据。
主要发现
- 染色体嵌合体在人类胚胎中已记录三十年。
- 早期PGT-A未测量嵌合体,可能避免问题但回顾看或导致误诊。
- 现代PGT-A评估多细胞活检标本,能识别染色体或亚染色体区域的中间拷贝数信号。
- 近期数据显示嵌合体本身及PGT-A检测到的特定嵌合体特征与可变临床结局相关。
临床怎么用
- 临床胚胎选择时应考虑嵌合体信息以改善决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chromosomal mosaicism, the coexistence of cells with different chromosomal content, has been documented in human embryos for 3 decades. Early versions of preimplantation genetic testing for aneuploidy (PGT-A) did not measure mosaicism, either because typically only a single cell was assessed or because the technique could not accurately identify it. Although this led to a straightforward diagnosis (an embryo was considered either normal or abnormal), it simply avoided the issue and, in hindsight, may have led to numerous misdiagnoses with negative clinical consequences. Modern PGT-A evaluates a multicellular biopsy specimen with techniques capable of recognizing intermediate copy number signals for chromosomes or subchromosomal regions. We are, therefore, inevitably confronted with the issue of mosaicism and the challenge of managing embryos producing such results in the clinic. Here we discuss recent data showing that not only mosaicism in general, but specific features of mosaicism detected with PGT-A, are associated with variable clinical outcomes. The conclusion is evident: mosaicism should be considered for more informed and improved embryo selection in the clinic.
引用
- Viotti M, McCoy RC, Griffin DK, et al. Let the data do the talking: the need to consider mosaicism during embryo selection. Fertil Steril. 2021. PMID: 34627598. doi:10.1016/j.fertnstert.2021.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。